<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01930461</url>
  </required_header>
  <id_info>
    <org_study_id>VO72.12</org_study_id>
    <nct_id>NCT01930461</nct_id>
  </id_info>
  <brief_title>Dose Ranging Study of SLIT Tablets of House Dust Mite Allergen Extracts (HDM) in Adults With HDM-associated Allergic Asthma</brief_title>
  <official_title>A Dose Ranging Study Investigating the Efficacy and Safety of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts in Adults With House Dust Mite-associated Allergic Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stallergenes Greer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stallergenes Greer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the efficacy and safety of different doses of
      sublingual tablets of house dust mite allergen extracts as compared to placebo in adults with
      house dust mite-associated allergic asthma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect on the Asthma control test (ACT) score</measure>
    <time_frame>13 months</time_frame>
    <description>Assessment of the effect of one year of treatment of 3 different doses of sublingual immunotherapy tablets of house dust mite (HDM) allergen extracts as compared to placebo on the Asthma Control Test™ (ACT) score, in adults with HDM-associated allergic asthma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number and percentage of subjects with treatment-emergent AEs</measure>
    <time_frame>Measured during 13 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes of Immunological parameters (HDM-specific IgE and IgG4 values)</measure>
    <time_frame>13 months</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">386</enrollment>
  <condition>Asthma</condition>
  <condition>House Dust Mite Allergy</condition>
  <arm_group>
    <arm_group_label>SLIT (A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SLIT tablets of HDM allergen extracts, 3 different doses (A)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SLIT (B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SLIT tablets of HDM allergen extracts, 3 different doses (B)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SLIT (C)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SLIT tablets of HDM allergen extracts, 3 different doses (C)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo matching the SLIT tablets of HDM allergen extracts</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SLIT tablets of HDM allergen extracts, 3 different doses (A)</intervention_name>
    <description>Two sublingual tablets daily for 13 months</description>
    <arm_group_label>SLIT (A)</arm_group_label>
    <other_name>Sublingual immunotherapy tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SLIT tablets of HDM allergen extracts, 3 different doses (B)</intervention_name>
    <description>Two sublingual tablets daily for 13 months</description>
    <arm_group_label>SLIT (B)</arm_group_label>
    <other_name>Sublingual immunotherapy tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SLIT tablets of HDM allergen extracts, 3 different doses (C)</intervention_name>
    <description>Two sublingual tablets daily for 13 months</description>
    <arm_group_label>SLIT (C)</arm_group_label>
    <other_name>Sublingual immunotherapy tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo matching the SLIT tablets of HDM allergen extracts</intervention_name>
    <description>Two sublingual tablets daily for 13 months</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sublingual placebo tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent.

          -  Male or female from 18 to 50 years of age.

          -  Diagnosed asthma and rhinitis with medical history consistent with HDM-induced
             allergic asthma and rhinitis.

          -  Positive SPT to HDM and and HDM-specific IgE serum value ≥ 0.7 kU/L.

          -  Stable asthma therapies.

          -  Spirometry (pre-bronchodilator) with best FEV1 ≥ 70% of the predicted value.

          -  Spirometry with reversibility in FEV1 of ≥ 12% and ≥ 200 mL.

          -  Asthma Control Test™ (ACT) score ≤ 19.

        Exclusion Criteria:

          -  Former smoker with &gt; 10 pack year history or current smoker.

          -  Patient with a urine level of cotinine ≥ 500 ng/mL.

          -  Co-sensitisation to any allergen possibly leading to clinically relevant symptoms
             likely to significantly change the asthma symptoms of the subject during the study.

          -  Patient who received allergen immunotherapy for HDM within the past 10 years.

          -  Ongoing immunotherapy for an aeroallergen other than house dust mite.

          -  Patient with any oral condition that could confound the safety assessments or planning
             to have a dental extraction during the study.

          -  Patient treated with beta-blockers, tricyclic antidepressants or monoamine oxidase
             inhibitors (MAOIs).

          -  Pregnant women or breast-feeding/lactating.

          -  Women with childbearing potential who are not using a medically accepted birth control
             method.

          -  Patient with a past or current disease, which as judged by the Investigator, may
             affect the patient's participation in, or the outcome of this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pascal Demoly, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montpellier, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Arnaud de Villeneuve</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHC, Hôpitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Berlin - Allergie-Centrum-Charité</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPZOZ Uniwersytecki Szpital Kliniczny Nr 1im.N.Barlickiego w Uniwersystetu Medycznego w Łodzi</name>
      <address>
        <city>Lodz</city>
        <zip>90-153</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Majorek-Olechowska Bernadetta</name>
      <address>
        <city>Tarnow</city>
        <zip>33-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 16, 2013</study_first_submitted>
  <study_first_submitted_qc>August 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2013</study_first_posted>
  <last_update_submitted>December 17, 2015</last_update_submitted>
  <last_update_submitted_qc>December 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

